Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neungseon Seo

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Ophthalmology and Therapy|November 6, 2024
Nonclinical Similarity of the Biosimilar Candidate ABP 938 with Aflibercept Reference ProductNeungseon Seo, Scott Kuhns, Dina A Andrews, et al.
Biologicals : Journal of the International Association of Biological Standardization|September 5, 2020
Analytical and functional similarity of biosimilar ABP 798 with rituximab reference productNeungseon Seo, Zhe Huang, Scott Kuhns, et al.
Immunotherapy|May 11, 2022
A review of the totality of evidence in the development of ABP 798, a rituximab biosimilarPatrick Cobb, Dietger Niederwieser, Stanley Cohen, et al.
The Journal of Biological Chemistry|August 3, 2010
An engineered alpha1 integrin-binding collagenous sequenceNeungseon Seo, Brooke H Russell, Jose J Rivera, et al.
Mabs|March 20, 2018
Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumabNeungseon Seo, Alla Polozova, Mingxuan Zhang, et al.
Ophthalmology and Therapy|March 20, 2024
Analytical and Functional Similarity of Aflibercept Biosimilar ABP 938 with Aflibercept Reference ProductNeungseon Seo, Xiaoyan Guan, Tian Wang, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Ophthalmology and Therapy|November 6, 2024
Nonclinical Similarity of the Biosimilar Candidate ABP 938 with Aflibercept Reference ProductNeungseon Seo, Scott Kuhns, Dina A Andrews, et al.
Biologicals : Journal of the International Association of Biological Standardization|September 5, 2020
Analytical and functional similarity of biosimilar ABP 798 with rituximab reference productNeungseon Seo, Zhe Huang, Scott Kuhns, et al.
Immunotherapy|May 11, 2022
A review of the totality of evidence in the development of ABP 798, a rituximab biosimilarPatrick Cobb, Dietger Niederwieser, Stanley Cohen, et al.
The Journal of Biological Chemistry|August 3, 2010
An engineered alpha1 integrin-binding collagenous sequenceNeungseon Seo, Brooke H Russell, Jose J Rivera, et al.
Mabs|March 20, 2018
Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumabNeungseon Seo, Alla Polozova, Mingxuan Zhang, et al.
Ophthalmology and Therapy|March 20, 2024
Analytical and Functional Similarity of Aflibercept Biosimilar ABP 938 with Aflibercept Reference ProductNeungseon Seo, Xiaoyan Guan, Tian Wang, et al.
Pageof 1